Vimpat(lacosamide)
Lacosamide, Motpoly, Vimpat (lacosamide) is a small molecule pharmaceutical. Lacosamide was first approved as Vimpat on 2008-08-29. It is used to treat epilepsy, lennox gastaut syndrome, partial epilepsies, and tonic-clonic epilepsy in the USA. It has been approved in Europe to treat epilepsy and partial epilepsies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Lacosamide, Motpoly, Vimpat (discontinued: Lacosamide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lacosamide | ANDA | 2025-04-09 |
| lacosamide oral solution | ANDA | 2025-02-12 |
| motpoly xr | New Drug Application | 2024-10-17 |
| vimpat | New Drug Application | 2024-09-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| epilepsy | EFO_0000474 | D004827 | G40.9 |
| lennox gastaut syndrome | — | D065768 | G40.81 |
| partial epilepsies | EFO_0004263 | D004828 | — |
| tonic-clonic epilepsy | EFO_0007262 | D004830 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
123 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | 9 | 20 | 4 | 5 | 38 |
| Seizures | D012640 | — | G40.4 | — | 8 | 16 | 2 | 5 | 30 |
| Partial epilepsies | D004828 | EFO_0004263 | — | — | 3 | 5 | 3 | 4 | 14 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 4 | 7 | — | — | 9 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | 2 | 5 | — | — | 5 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 3 | — | — | 4 |
| Complex partial epilepsy | D017029 | EFO_1000877 | — | — | — | 3 | — | — | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuralgia | D009437 | EFO_0009430 | — | — | 3 | — | — | — | 3 |
| Postherpetic neuralgia | D051474 | — | — | — | 3 | — | — | — | 3 |
| Epileptic syndromes | D000073376 | — | — | — | 1 | — | — | — | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 1 | — | — | — | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 1 | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | — | — | 1 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | 1 | — | — | — | 1 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
| Partial epilepsy motor | D020938 | EFO_1001089 | — | — | — | — | — | 1 | 1 |
| Traumatic brain injuries | D000070642 | — | S06 | — | — | — | — | 1 | 1 |
| Brain injuries | D001930 | — | S06.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lacosamide |
| INN | lacosamide |
| Description | Lacosamide is a N-acyl-amino acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 175481-36-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL58323 |
| ChEBI ID | — |
| PubChem CID | 219078 |
| DrugBank | DB06218 |
| UNII ID | 563KS2PQY5 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Lacosamide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
23,450 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use